News | August 03, 2008

Abnormal Heart Rate Turbulence Predicts Sudden Death in Patients with CHF

August 4, 2008 – New research shows abnormal heart rate turbulence (HRT), an ECG-based risk marker, is a significant risk predictor for sudden death in patients with congestive heart failure (CHF).

The study published in the August edition of the HeartRhythm Journal, the official journal of the Heart Rhythm Society, is the first to document abnormal HRT as an indicator of sudden, or arrhythmic death risk in patients with heart failure.

The MUSIC (Muerte Subita en Insufficiencia Cardiaca) Study, a multi-center, Spanish, longitudinal study designed to assess risk markers for sudden death in CHF patients, represents the largest heart failure population ever studied. More than 1,000 patients were enrolled in the MUSIC Study between 2003 and 2004 and several risk markers, including Holter-based, were assessed to predict mortality during nearly four years of follow up. Led by principal investigator Antoni Bayes de Luna, M.D., this is the first study to document that HRT predicts not only all-cause mortality and heart failure progression, but also sudden death in patients with heart failure.

“Our study documented that HRT might be considered a useful tool to identify heart failure patients at high risk of death, including high risk of dying suddenly,” said lead author Iwona Cygankiewicz, M.D., Ph.D., cardiology division, University of Rochester Medical Center in New York. “HRT may help physicians more effectively manage heart failure patients by indicating the need for more frequent follow up visits at specialized heart failure units and more intensely applied therapy, including ICD implantation in high risk patients.”

About 50 percent of congestive heart failure-related deaths are due to progressive heart failure, while the other half are thought to be related to serious arrhythmias. Even though HRT was proven as an important risk startifier in postinfarction patients, little is known about its value in patients with heart failure. Previous, smaller studies have proven abnormal HRT as a risk stratifier for all-cause mortality and heart failure progression, but not sudden death.

Patients of the MUSIC study represent a modern population of heart failure patients with a broad spectrum of etiologies. The study population includes patients with heart failure as seen at the ambulatory practice, including a high number of patients with preserved left ventricular ejection fraction (LVEF). Interest is growing in the survival of patients with preserved LVEF and the MUSIC study marks the first time this subgroup was included in a study evaluating the prognostic value of HRT.

For more information: www.heartrhythmjournal.com


Related Content

News | Cardiovascular Clinical Studies

May 6, 2026 — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions ...

Home May 06, 2026
Home
News | Cardiovascular Clinical Studies

April 9, 2026 — Mount Sinai researchers have created an analytic tool using machine learning that can predict ...

Home April 14, 2026
Home
News | Cardiovascular Clinical Studies

April 13, 2026 —The American Heart Association (AHA) has granted Case Western Reserve University the Rapid Impact ...

Home April 13, 2026
Home
News | Cardiovascular Clinical Studies

April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance ...

Home April 02, 2026
Home
News | Cardiovascular Clinical Studies

March 4, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced Late-Breaking clinical ...

Home March 04, 2026
Home
News | Cardiovascular Clinical Studies

Feb. 9, 2026 — HTA and MedAxiom have opened applications for the 2026 HeartX program, a cardiovascular-focused ...

Home February 18, 2026
Home
News | Cardiovascular Clinical Studies

Jan. 5, 2026 — Medera Inc., a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by ...

Home January 05, 2026
Home
News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
Subscribe Now